Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
Thorax. 2021 Mar;76(3):248-255. doi: 10.1136/thoraxjnl-2020-215917. Epub 2020 Dec 9.
There is limited knowledge regarding the quality of dying and death (QODD) and end-of-life interventions in patients with interstitial lung disease (ILD). Hence, differences in QODD and end-of-life interventions between patients with ILD and those with lung cancer (LC) remain poorly understood.
The primary aim of this study was to explore the differences in QODD and end-of-life interventions among patients dying with ILD versus those dying with LC. We performed a mail survey to quantify the QODD of a bereaved family's perspective using the Good Death Inventory (GDI) score. Moreover, we examined the end-of-life interventions by medical chart review.
Of 361 consecutive patients analysed for end-of-life interventions, 167 patients whose bereaved families completed questionnaires were analysed for QODD. Patients with ILD had lower GDI scores for QODD than those with LC (p=0.04), particularly in domains related to 'physical and psychological distress relief' and 'prognosis awareness and participation in decision making' (p=0.02, respectively). In end-of-life interventions, patients with ILD were less likely to receive specialised palliative care services (8.5% vs 54.3%; p<0.001) and opioids (58.2% vs 73.4%; p=0.003). Additionally, lower frequencies of participation of patients with ILD in end-of-life discussion were also observed (40.8% vs 62.4%; p=0.007).
Patients with ILD had lower QODD and poorer access to palliative care and decision making than those with LC. Additional efforts to improve QODD in patients with ILD, particularly in symptom relief and decision-making processes, are urgently warranted.
对于间质性肺疾病(ILD)患者的临终和死亡质量(QODD)以及生命末期干预措施,我们知之甚少。因此,ILD 患者与肺癌(LC)患者之间的 QODD 和生命末期干预措施的差异仍了解甚少。
本研究的主要目的是探讨ILD 患者死亡与 LC 患者死亡之间 QODD 和生命末期干预措施的差异。我们通过邮件调查使用 Good Death Inventory(GDI)评分来量化从丧亲家庭的角度来看的 QODD。此外,我们通过病历回顾检查了生命末期的干预措施。
在分析了 361 例生命末期干预措施的连续患者中,有 167 例丧亲家庭完成了问卷的 ILD 患者被用于 QODD 分析。ILD 患者的 QODD 评分低于 LC 患者(p=0.04),特别是在与“身体和心理痛苦缓解”和“预后意识和参与决策”相关的领域(分别为 p=0.02)。在生命末期的干预措施中,ILD 患者接受专门的姑息治疗服务的可能性较小(8.5%对 54.3%;p<0.001),接受阿片类药物的可能性也较小(58.2%对 73.4%;p=0.003)。此外,ILD 患者参与生命末期讨论的频率也较低(40.8%对 62.4%;p=0.007)。
ILD 患者的 QODD 较低,获得姑息治疗和决策的机会较差,比 LC 患者差。迫切需要进一步努力改善 ILD 患者的 QODD,特别是在缓解症状和决策过程方面。